Table 2.
Effects of C10TAB on intracellular ATP levels and ATP/ADP ratios in MDCK cells after 3 h of exposure to C10TAB
| Treatment | Concn (mM) | Mean ± SDa |
|
|---|---|---|---|
| ATP (%)b | ATP/ADP ratio | ||
| Control | 0 | 100.0 ± 10.3 | 2.9 ± 0.5 |
| C10TAB | |||
| CMC/300 | 0.13 | 101.7 ± 11.2 | 2.4 ± 0.3 |
| CMC/100 | 0.40 | 98.0 ± 7.1 | 2.2 ± 0.4 |
| CMC/30 | 1.33 | 84.4 ± 16.1 | 1.4 ± 0.3** |
| CMC/20 | 2.00 | 77.5 ± 13.6* | 1.3 ± 0.4*** |
| CMC/10 | 4.00 | 53.4 ± 12.8*** | 1.1 ± 0.4*** |
| CMC/3 | 13.33 | 0.8 ± 0.5*** | 0.2 ± 0.3*** |
| Staurosporin | 0.001 | 65.4 ± 10.9** | ND |
a
Data are means of at least three independent experiments. ND, not determined. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (significant differences from the respective control).
b
Results were normalized to protein content and are expressed as the percentage of mock-treated control cells (24.07 ± 2.48 nmol of ATP/mg of protein).